Medical device compliance tightened across three of the world’s largest markets at once in mid-2026, making devices and IVDs the busiest area of Life Sciences regulation we tracked. The EU pushed its device database toward mandatory use, the US FDA enforced on device quality, and China kept adjusting its registration machinery. None is dramatic alone, but together they raise the baseline for keeping products on the market, and the obligations are converging on data, quality systems, and registration discipline.
EUDAMED has become mandatory across the EU
The European Commission set mandatory use of the first four EUDAMED modules, and national agencies (Estonia’s Medicines Agency among them) confirmed the database is now obligatory in practice. EUDAMED has been “coming” for years, which bred complacency; the shift to mandatory is the moment that complacency becomes a liability. Manufacturers and importers need actor registration, device identification, and the relevant submissions in order, because incomplete EUDAMED data increasingly means a market-access problem rather than an administrative one. The work is unglamorous, but it is now gating, and back-filling it under time pressure is far harder than building it in.
An FDA warning letter targeted device quality systems
The FDA issued a warning letter to ZOLL Medical over quality-system and medical-device-reporting deficiencies. Warning letters like this are a reminder that post-market obligations (complaint handling, corrective and preventive action, adverse-event reporting) are actively policed, not just gating requirements cleared at approval. A quality-system gap that looks like internal paperwork becomes a public enforcement record quickly, drawing scrutiny from customers, partners, and other regulators who read the same letters. Remediation under a warning letter is slower and costlier than getting the system right the first time.
China kept updating device registration and classification
China’s NMPA updated device registration and filing requirements following classification adjustments, while the CMDE consulted on multiple draft technical guidelines. China’s device framework has been in near-constant motion, and classification changes are deceptively disruptive: a reclassified device can face a different evidence bar, filing route, or timeline, sometimes mid-programme. Manufacturers selling into China should monitor classification and guidance changes continuously and treat registration as an ongoing relationship with a moving framework, not a one-time event.
What does this mean for manufacturers?
The EU, US, and China are tightening different levers (database completeness, post-market quality enforcement, and registration requirements) but the combined effect is a higher, more data-intensive baseline. Treat EUDAMED enrollment, quality-system readiness, and Chinese classification status as live obligations, market by market, rather than milestones cleared once at launch. In device regulation, the expensive surprises almost always come from something that was compliant at approval and quietly stopped being so. RegASK tracks device and IVD regulation across 160+ markets, helping manufacturers see classification, database, and enforcement changes early enough to act.
